Surprisingly, Post-COVID-19 Pulmonary Fibrosis Tends to Resolve
Pulmonary fibrosis caused by severe COVID-19 shows a surprising tendency to resolve, offering new insights that may inform treatments for non-resolving forms of the disease.
Pulmonary fibrosis caused by severe COVID-19 shows a surprising tendency to resolve, offering new insights that may inform treatments for non-resolving forms of the disease.
Pulmonary fibrosis caused by severe COVID-19 shows a surprising tendency to resolve, offering new insights that may inform treatments for non-resolving forms of the disease.
Read MoreDeupirfenidone showed an 80.9% treatment effect compared to placebo at the higher dose studied, while pirfenidone had a 54.1% treatment effect versus placebo.
Read MoreThe online resource aims to offer patients with pulmonary fibrosis and interstitial lung disease guidance and support in the early months after diagnosis.
Read MorePreclinical data reveals CAN10’s potential to target key proteins involved in systemic sclerosis-associated interstitial lung disease and idiopathic pulmonary fibrosis.
Read MoreCordyceps sinensis, a traditional Chinese medicinal fungus, alleviated IPF in mice by inhibiting mitochondrion-mediated oxidative stress.
Read MoreThe Pulmonary Fibrosis Foundation has announced the appointment of a new president and CEO, following a period of interim leadership.
Read MoreAgomab Therapeutics received FDA Orphan Drug Designation for AGMB-447, an inhaled lung-restricted ALK5-inhibitor for idiopathic pulmonary fibrosis.
Read MoreAGMB-447, a small-molecule inhibitor of ALK5, is being evaluated in a phase 1 clinical trial.
Read MoreA multinational clinical trial found that the drug candidate did not significantly slow the progression of idiopathic pulmonary fibrosis compared to a placebo.
Read MoreResearchers have identified a molecular pathway that leverages the body’s natural healing processes to potentially reverse idiopathic pulmonary fibrosis.
Read MoreFive PFF Scholars will each receive a $100,000 research grant over two years to improve the understanding of pulmonary fibrosis and advance successful treatments.
Read MoreSurprisingly, one bacterial species tended to dominate in certain patients with IPF who were not treated with antibiotics—and those patients were more likely to survive.
Read MoreThe new company, formed through a merger between Oxitope and Arxx, has a pipeline of selective antibodies that target inflammatory and fibrotic indications, including several first-in-class clinical candidates.
Read MoreEighty-five percent of idiopathic pulmonary fibrosis patients suffer from chronic cough, but low-dose, controlled morphine may offer some relief.
Read MoreAccording to Imvaria, the device’s manufacturer, the clearance signifies the first FDA authorization of a diagnostic tool of any type in lung fibrosis.
Read MoreHigher levels of omega-3 fatty acids were associated with better lung function and longer transplant-free survival in patients with pulmonary fibrosis, a new study finds.
Read MoreAileron Therapeutics acquired Lung Therapeutics Inc, a biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications.Â
Read MoreThe Pulmonary Fibrosis Foundation and Pulmonary Hypertension Association have developed a position statement that addresses gaps in the diagnosis and treatment of patients living with pulmonary hypertension related to interstitial lung disease.
Read MoreCHEST announced the recipients of quality improvement grants aimed at shortening the time to diagnosis for interstitial lung disease.Â
Read MoreTwo studies presented at CHEST 2023 validated the effectiveness of the Envisia Genomic Classifier in improving the detection of interstitial lung disease.
Read MoreThe Pulmonary Fibrosis Foundation announced that seven medical centers have joined the PFF Care Center Network as clinical associate members, a new membership option.Â
Read MoreNew data presented at the CHEST Annual Meeting supports the improved tolerability of LYT-100 over FDA-approved pirfenidone and provides insights into dose selection.
Read MoreThe Pulmonary Fibrosis Foundation announced Franck Rahaghi, MD, MHS, FCCP, as its incoming president, CEO, and chief medical officer, effective Sept 15.
Read MoreThe phase 2 clinical trial is expected to be a multi-center, randomized, double-blind, placebo-controlled study assessing the drug’s safety and effectiveness in treating approximately 90 pulmonary sarcoidosis patients.
Read More